Skip to main content

Table 3 Area under the receiver operating curves in training, test, and combined sets

From: A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA

 

# of markers

Model

AUC/Train (25/58)a

AUC/Test (13/29)a

AUC/ALL (87)b

DRE

2

HOXA7, HOXB5

0.897

0.898

0.892

3

HOXA7, HOXB5, HOXD3b

0.911

0.869

0.898

4

HOXA7, HOXB5, HOXD3b, AOX1rc

0.915

0.875

0.91

5

ADCY4, HOXA7, HOXB5, NODAL, MOXD1

0.89

0.909

0.9

5

HOXA7, HOXD10, APC, GFRA2, KIFC2

0.892

0.886

0.888

6

HOXA7, HOXB5, HOXD3b, HOXD9, GFRA2, AOX1rc

0.907

0.875

0.897

7

HOXA7, HOXB5, HOXD3b, HOXD10, KIFC2, AOX1rc, HOXD3a

0.912

0.875

0.903

8

ADCY4, HOXA7, HOXD3b, HOXB5, HOXD9, HOXD10, NODAL, KIFC2rc

0.891

0.847

0.876

11

ADCY4, HOXA7, HOXB5, HOXD9, GSTP1, RASSF5, EPHX3, HEMK1rc, KIFC2, MOXD1, AOX1rc

0.916

0.949

0.925

 

# of markers

Model

AUC/Train (20/45)a

AUC/Test (12/22)a

AUC/ALL (67)b

FV

2

HOXD3b, RASSF5

0.902

0.936

0.915

3

HOXB5, HOXD3b, RASSF5

0.866

0.891

0.873

3

HOXD3b, MOXD1, RASSF5

0.915

0.936

0.926

4

ADCY4, HOXD3b, RASSF5, KIFC2

0.858

0.827

0.854

6

HOXB5, HOXD3b, MOXD1, RASSF5, CXCL14, KIFC2

0.894

0.845

0.88

8

ADCY4, HOXD3b, HOXD10, HOXD3a, MOXD1, RASSF5, CXCL14, GSTP1

0.902

0.882

0.895

8

ADCY4, HOXB5, HOXD3b, HOXA7, HOXD9, HOXD3a, RASSF5, AOX1rc

0.824

0.891

0.846

8

ADCY4, HOXA7, HOXD3b, HOXB5, HOXD9, HOXD10, NODAL, KIFC2rc

0.822

0.882

0.833

  1. The AUCs for training and test sets as well as the combined (ALL) set for select model marker combinations and all 19 markers
  2. aThe numbers in the parentheses are the number of cases/total number of patients
  3. bThe number in the parentheses represents the combined training and test sets